

Res. Asst. PhD SELİN ÖNCÜL

Personal Information

Office Phone: +90 312 305 0000 Extension: 1499

Email: selin.oncul@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/selin.oncul>

Education Information

Doctorate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Tıbbi Biyokimya, Turkey 2014 - 2017

Postgraduate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Tıbbi Biyokimya, Turkey 2011 - 2013

Undergraduate, Ankara University, Fen Fakültesi/Fen Bilimleri Enstitüsü, Biyoloji Bölümü, Turkey 2006 - 2010

Foreign Languages

English, C2 Mastery

Certificates, Courses and Trainings

Vocational Training, Doktora sonrası araştırma, The University of Texas MD Anderson Cancer Center The Department of Experimental Therapeutics, 2018

Dissertations

Doctorate, Doksorubisinin luminal A ve üçlü negatif meme kanseri hücrelerinde P53 apoptoz yolağı ve çoklu ilaç direnci üzerinde farklı etkilerinin incelenmesi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Biyokimya (Dr), 2017

Postgraduate, Karaciğer ve meme kanseri hücreleri ile embriyonik böbrek hücrelerinde doksorubisinin apoptotik genlerin ve MDR-1 geninin ekspresyon düzeylerine etkisi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü, Biyokimya (YI) (Tezli), 2013

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Biochemistry

Academic Titles / Tasks

Research Assistant, Hacettepe University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 2012 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on

HepG2 cancer cell lines

Şenol Y., KAPLAN O., VARAN C., Demirtürk N., Öncül S., Fidan B. B., ERCAN A., BİLENSOY E., ÇELEBİER M.
Journal of Drug Delivery Science and Technology, vol.79, 2023 (SCI-Expanded)

- II. **Plasma irisin and metabolomic response differ between concentric and isometric exercise Effets différents de l'exercice concentrique et de l'exercice isométrique sur l'irisine plasmatique et la réponse métabolomique**
KARA Ö. S., ERCAN A., ÇELEBİER M., KAPLAN O., ÖNCÜL S., KORKUSUZ F.
Science and Sports, vol.37, no.7, pp.610-617, 2022 (SCI-Expanded)
- III. **Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells**
Varol I., KAPLAN O., Erdoğan N., Öncül S., Nielsen T. T., ERCAN A., BİLENSOY E., ÇELEBİER M.
Current Pharmaceutical Analysis, vol.17, no.10, pp.1272-1281, 2021 (SCI-Expanded)
- IV. **An investigation of the effect of surface characterization on Saos-2 cell proliferation after coating of titanium alloy surfaces by a selective laser melting process**
Olçay E. O., ERCAN A., ÖNCÜL S., Arifagaoglu O., ERSU B.
Surface and Coatings Technology, vol.422, 2021 (SCI-Expanded)
- V. **Antitumor activity of Ankaferd Blood Stopper (R) on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action**
Zeki O. C., NENİ M., ÇELEBİER M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., Haznedarog I. C.
JOURNAL OF HERBAL MEDICINE, vol.28, 2021 (SCI-Expanded)
- VI. **Polycationic cyclodextrin nanoparticles induce apoptosis and affect antitumoral activity in HepG2 cell line: An evaluation at the molecular level**
ERCAN A., ÇELEBİER M., ÖNCÜL S., VARAN G., KOÇAK E., Benito J. M., BİLENSOY E.
International Journal of Pharmaceutics, vol.598, 2021 (SCI-Expanded)
- VII. **An allomaltol derivative triggers distinct death pathways in luminal a and triple-negative breast cancer subtypes**
ERCAN A., ÖNCÜL S., Karakaya G., Aytemir M.
BIOORGANIC CHEMISTRY, vol.105, 2020 (SCI-Expanded)
- VIII. **Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum**
Oncul S., Amero P., Rodriguez-Aguayo C., Calin G. A., Sood A. K., Lopez-Berestein G.
RNA BIOLOGY, vol.17, no.11, pp.1523-1534, 2020 (SCI-Expanded)
- IX. **The interaction between the complement system and hemostatic factors**
ÖNCÜL S., Afshar-Kharghan V.
CURRENT OPINION IN HEMATOLOGY, vol.27, no.5, pp.341-352, 2020 (SCI-Expanded)
- X. **A kojic acid derivative promotes intrinsic apoptotic pathway of hepatocellular carcinoma cells without incurring drug resistance**
ÖNCÜL S., Karakaya G., Dilsiz Aytemir M., ERCAN A.
Chemical Biology and Drug Design, vol.94, no.6, pp.2084-2093, 2019 (SCI-Expanded)
- XI. **Synthesis, computational molecular docking analysis and effectiveness on tyrosinase inhibition of kojic acid derivatives**
Karakaya G., TÜRE A., ERCAN A., ÖNCÜL S., Aytemir M.
Bioorganic Chemistry, vol.88, 2019 (SCI-Expanded)
- XII. **HGF-1 proliferation on titanium dental implants treated with laser melting technology**
Arifagaoglu O., ÖNCÜL S., ERCAN A., Olçay O., ERSU B.
NIGERIAN JOURNAL OF CLINICAL PRACTICE, vol.22, no.2, pp.251-257, 2019 (SCI-Expanded)
- XIII. **Synthesis and Cytotoxic Evaluation of Kojic Acid Derivatives with Inhibitory Activity on Melanogenesis in Human Melanoma Cells**
KARAKAYA G., ÖNCÜL S., ERCAN A., AYTEMİR M.
Anti-Cancer Agents In Medicinal Chemistry, vol.18, pp.1-12, 2018 (SCI-Expanded)
- XIV. **Global omics strategies to investigate the effect of cyclodextrin nanoparticles on MCF-7 breast cancer cells**

ERCAN A., ÇELEBİER M., VARAN G., ÖNCÜL S., Nenni M., KAPLAN O., BİLENSOY E.

European Journal of Pharmaceutical Sciences, vol.123, pp.377-386, 2018 (SCI-Expanded)

- XV. **Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis**

ÖNCÜL S., ERCAN A.

INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.79, no.4, pp.599-607, 2017 (SCI-Expanded)

- XVI. **Cholesterol-Targeted Anticancer and Apoptotic Effects of Anionic and Polycationic Amphiphilic Cyclodextrin Nanoparticles**

VARAN G., ÖNCÜL S., ERCAN A., BENITO J. M., MELLET C. O., BİLENSOY E.

Journal of Pharmaceutical Sciences, vol.105, no.10, pp.3172-3182, 2016 (SCI-Expanded)

Articles Published in Other Journals

- I. **Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper (R) Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies**

NENNI M., ÖNCÜL S., ERCAN A., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.

CURRENT TRADITIONAL MEDICINE, vol.7, no.2, pp.223-235, 2021 (ESCI)

- II. **Comparison of cell lysis techniques via q-tof lc/ms**

KAPLAN O., ÖNCÜL S., ERCAN A., ÇELEBİER M.

Mass Spectrometry Letters, vol.11, no.2, pp.36-40, 2020 (ESCI)

- III. **Kojic acid derivatives as potential anticancer agents: Synthesis and cytotoxic evaluation on A375 human malignant melanoma cells**

Karakaya G., ERCAN A., ÖNCÜL S., Aytemir M.

JOURNAL OF RESEARCH IN PHARMACY, vol.23, no.4, pp.596-607, 2019 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Proteomic Investigation of Ankaferd Hemostat Application on MCF-7 Breast Cancer Cell Line**

ZEKİ Ö. C., NENNI M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., HAZNEDAROĞLU İ. C.

International Multidisciplinary Symposium on Drug Research and Development (DRD), 1 - 03 July 2019

- II. **A Metabolomic Study to Investigate the Effect of Folate Conjugated Nanoparticles on Triple Negative Breast Cancer Cells**

ERCAN A., ÇELEBİER M., varol İ., KAPLAN O., Varan G., ÖNCÜL S., KOÇAK E., BİLENSOY E.

EUFEPS Annual Meeting 2019 PERSONALIZED MEDICINES,TARGETED THERAPIES,PRECISION DRUG DELIVERY, 6 - 08 March 2019

- III. **Breast cancer treatment capacity of an allomaltol derivative from the standpoint of apoptosis and multidrug resistance**

ÖNCÜL S., ERCAN A., KARAKAYA G., AYTEMİR M.

FEBS OPEN BIO, 7 - 12 July 2018, vol.8, pp.298

- IV. **The effect of polycationic amphiphilic cyclodextrin nanoparticles on mda-mb cancer cells: A metabolomic approach to understand the mechanism**

ÇELEBİER M., KAPLAN O., VARAN G., ÖNCÜL S., KOÇAK E., ERCAN A., BİLENSOY E.

12 th International symposium on pharmaceutical sciences, 26 June 2018

- V. **Investigation of The Effect of Commercial Herbal Mixture on HepG2 Liver Cancer Cell Line by Proteomic Approach**

NENNI M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., ÇELEBİER M., HAZNEDAROĞLU İ. C.

12th International Symposium on Pharmaceutical Sciences, 26 - 29 June 2018

- VI. **Breast Cancer Treatment Capacity of a Allomaltol Derivative from the Standpoint of Apoptosis and Multidrug Resistance**

ÖNCÜL S., ERCAN A., KARAKAYA G., AYTEMİR M.

The 43rd FEBS Congress, Prag, Czech Republic, 07 June 2018, pp.1

VII. GENOMIC AND METABOLOMIC STUDIES OF POLYCATIONIC AMPHIPHILIC CYCLODEXTRIN NANOPARTICLES ON HEPG2 CELL LINE

ERCAN A., ÇELEBİER M., Varan G., ÖNCÜL S., KOÇAK E., KAPLAN O., BİLENSOY E.

EUFEPS Annual Meeting 2018 Crossing Barriers for Future Medicines, 24 - 26 May 2018

VIII. Synthesis of Some New Mannich Bases with Anti-tyrosinase Activity.

AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.

2nd International Gazi Pharma Symposium Series (GPSS), 11 - 13 October 2017

IX. MCF-7 Breast Cell Proteome Analysis Determination With New UPLC/MS Method

KOÇAK E., ÖNCÜL S., NENİ M., Kaplan O., ÇELEBİER M., SÜSLÜ İ., ERCAN A., ALTINÖZ S.

Symposium on Drug Research Development, 5 - 07 October 2017

X. Screening for Cytotoxic Effects of Chlorokojic Acid Derivatives

AYTEMİR M., Karakaya G., ERCAN A., ÖNCÜL S.

Symposium on Drug Research And Development, 5 - 07 October 2017

XI. An in vitro investigation of human gingival fibroblast proliferation on dental titanium implants treated with selective laser melting technology

ARİFAĞAOĞLU Ö., ÖNCÜL S., ERCAN A., ERSU B.

26th Annual Scientific Meeting of the European Association for Osseointegration, Madrid, Spain, 5 - 07 October 2017, vol.28, pp.26

XII. Cytotoxic Effect of Allomaltol Derivative on A375 Human Malignant Melanoma and MCF7 Breast Cancer Cells

ERCAN A., AYTEMİR M., KARAKAYA G., ÖNCÜL S.

International Multidisciplinary Symposium on Drug Research Development (DRD2017), 5 - 07 October 2017

XIII. Screening for Cytotoxic Effects of Chkrokojic Acid Derivatives

AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.

International Multidisciplinary Symposium on Drug Research Development (DRD2017), 5 - 07 October 2017

XIV. Mild doses of doxorubicin alters apoptotic response and cell cycle arrest on both luminal A and triple negative breast cancer cell lines

ÖNCÜL S., ERCAN A.

42nd FEBS Congress, Israel, 10 - 14 September 2017, vol.284, pp.286

XV. CYTOTOXICITY OF A KOJIC ACID DERIVATIVE ON A375 HUMAN MALIGNANT MELANOMA AND HGF1 FIBROBLAST CELLS

AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.

10th Joint Meeting On Medicinal Chemistry, Dubrovnik, Croatia, 25 - 28 June 2017

XVI. Evaluation of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles for Cancer Therapy

VARAN G., ÖNCÜL S., ERCAN A., BENİTO J., MELLET C. O., BİLENSOY E.

Innovation in Medicine Meetings III Congress, 11 - 13 May 2017

XVII. Assessment of Low Dose Doxorubicin on Apoptosis and Multidrug Resistance in MCF 7 Cells

ERCAN A., ÖNCÜL S.

6. MOKAD, Konya, Turkey, 27 - 30 October 2016

Supported Projects

ERCAN A., ÖNCÜL S., Project Supported by Higher Education Institutions, Yeni Sentezlenen Bir Antrasiklin Türevinin Meme Kanseri Hücrelerinde p53 Apoptoz Yolağı ve Çoklu İlaç Direnci Üzerine Etkisi, 2016 - 2018

ERCAN A., AYTEMİR M., TUBITAK Project, Yeni Mannich Bazlarının Tirozinaz İnhibitörü Etkileri ve A375 İnsan Melanoma Hücreleri Üzerine Hücre Canlılıklarının Değerlendirilmesi, 2016 - 2017

UÇAR G., ERİKÇİ A., BAYSAL İ., ERCAN A., YÜKSEL TEK M., BİBEROĞLU K., TÜYLÜ KÜÇÜKKILINÇ Z. T., AYAZGÖK B., TACAL Ö., YABANOĞLU ÇİFTÇİ S., et al., Project Supported by Higher Education Institutions, ECF385 Biyokimya III Laboratuvar

Ders İçeriğinin Klinik Biyokimya Yöntemleri ile Zenginleştirilerek Güncellenmesi, 2015 - 2016

Metrics

Publication: 36

Citation (WoS): 88

Citation (Scopus): 166

H-Index (WoS): 5

H-Index (Scopus): 5

Congress and Symposium Activities

IV International Conference on Cancer Research & Drug Development, Attendee, Maryland, United States Of America, 2019

The University of Houston College Pharmacy Pharmacological and Pharmaceutical Sciences 2019 Research Symposium, Working Group, Texas, United States Of America, 2019

The 43rd FEBS EMBO Congress, Attendee, Praha, Czech Republic, 2018

The 42nd FEBS EMBO Congress, Attendee, Yerushalayim, Israel, 2017

METU Biochemistry Conference II, Audience, Ankara, Turkey, 2015

The 40th FEBS EMBO Congress, Attendee, Berlin, Germany, 2015

The Organization Committee of Advanced Technologies of Health Sciences Symposium, Audience, Ankara, Turkey, 2014

IFCC WorldLab 2014, Attendee, İstanbul, Turkey, 2014

The 38th FEBS EMBO Congress, Attendee, Sankt-Peterburg, Russia, 2013

Scholarships

TUBITAK 2219 Doktora Sonrası Araştırma Bursu, TUBITAK, 2018 - 2020

Awards

Öncül S., 21-23 Ekim 2019'da Baltimore, MD, ABD'de gerçekleşen IV. Kanser Araştırma & İlaç Geliştirme Uluslararası Kongresine sözlü sunum ile katılmak için seyahat ödülü, The University Of Texas Md Anderson Cancer Center Clyde H. Wright Memorial Fund, October 2019

Nenni M., Öncül S., Ercan A., Süslü İ., Çelebier M., Haznedaroğlu İ. C., Poster 3.lük ödülü, 12Th International Symposium On Pharmaceutical Sciences (Isops) 2018, July 2018

Ercan A., Çelebier M., Varan G., Öncül S., Koçak E., Kaplan O., Bilensoy E., Women in Pharmaceutical Scientists (WIPS), Eufeps 2018, May 2018